Biomedical Engineering Reference
In-Depth Information
53. Gavaghan CL, Arnby CH, Blomberg N et al (2007) Development, interpretation and
temporal evaluation of a global QSAR of hERG electrophysiology screening data. J Comput
Aided Mol Des 21:189-206
54. Shamovsky I, de Graaf C, Alderin L et al (2009) Increasing selectivity of CC chemokine
receptor 8 antagonists by engineering nondesolvation related interactions with the intended
and off-target binding sites. J Med Chem 52:7706-7723
55. Roy K, Ghosh G (2009) QSTR with extended topochemical atom (ETA) indices. 13.
Modelling of hERG K+ channel blocking activity of diverse functional drugs using different
chemometric tools. Mol Simulat 35:1256-1268
56. Diller DJ, Wang N, Delisle RK et al (2006) WO Patent WO2006055918
57. Diller DJ, Wang N, Delisle RK et al (2006) US Patent US20060206269
58. Diller DJ, Hobbs DW (2007) Understanding hERG inhibition with QSAR models based on a
one-dimensional molecular representation. J Comput Aided Mol Des 21:379-393
59. Bains W, Basman A, White C (2004) HERG binding specificity and binding site structure:
evidence from a fragment-based evolutionary computing SAR study. Prog Biophys Mol Biol
86:205-233
60. Tobita M, Nishikawa T, Nagashima R (2005) A discriminant model constructed by the
support vector machine method for HERG potassium channel inhibitors. Bioorg Med Chem
Lett 15:2886-2890
61. Roche O, Trube G, Zuegge J et al (2002) A virtual screening method for prediction of the
HERG potassium channel liability of compound libraries. Chembiochem 3:455-459
62. Dubus E, Ijjaali I, Petitet F et al (2006) In silico classification of HERG channel blockers: a
knowledge-based strategy. ChemMedChem 1:622-630
63. Thai KM, Ecker GF (2009) Similarity-based SIBAR descriptors for classification of chemi-
cally diverse hERG blockers. Mol Divers 13:321-336
64. Thai KM, Ecker GF (2008) Classification models for HERG inhibitors by counter-propaga-
tion neural networks. Chem Biol Drug Des 72:279-289
65. Thai KM, Ecker GF (2008) A binary QSAR model for classification of hERG potassium
channel blockers. Bioorg Med Chem 16:4107-4119
66. Chekmarev DS, Kholodovych V, Balakin KV et al (2008) Shape signatures: new descriptors
for predicting cardiotoxicity in silico. Chem Res Toxicol 21:1304-1314
67. Doddareddy MR, Klaasse EC, Shagufta et al. Prospective validation of a comprehensive in
silico hERG model and its applications to commercial compound and drug databases.
ChemMedChem 5:716-729
68. O'Brien SE, de Groot MJ (2005) Greater than the sum of its parts: combining models for
useful ADMET prediction. J Med Chem 48:1287-1291
69. Sun H (2006) An accurate and interpretable bayesian classification model for prediction of
HERG liability. ChemMedChem 1:315-322
70. Jia L, Sun H (2008) Support vector machines classification of hERG liabilities based on atom
types. Bioorg Med Chem 16:6252-6260
71. Buyck C, Tollenaere J, Engels M et al (8-13 Sep. 2002) The 14th European Symposium on
QSARs. Bournemouth, UK
72. Catana C (2009) Simple idea to generate fragment and pharmacophore descriptors and their
implications in chemical informatics. J Chem Inf Model 49:543-548
73. Redfern WS, Carlsson L, Davis AS et al (2003) Relationships between preclinical cardiac
electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range
of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58:
32-45
74. Yap CW, Cai CZ, Xue Y et al (2004) Prediction of torsade-causing potential of drugs by
support vector machine approach. Toxicol Sci 79:170-177
75. Skold C, Winiwarter S, Wernevik J et al (2006) Presentation of a structurally diverse and
commercially available drug data set for correlation and benchmarking studies. J Med Chem
49:6660-6671
